Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 3/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.37 |
| ▸ | CPN1 | P15169 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27166484 | 0.90 | ITGB3 (0.41) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL927784 | 0.84 | GABRA5 (0.39) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL345833 | 0.84 | SLC6A1 (0.32) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL4484354 | 0.79 | ITGB3 (0.46) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL222367 | 0.78 | SLC6A1 (0.49) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL3613801 | 0.78 | SLC6A1 (0.49) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL222368 | 0.78 | SLC6A1 (0.49) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL23826437 | 0.75 | GABRA5 (0.34) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 | |
| SCHEMBL21997973 | 0.74 | LSS (0.32) | ITGB3ITGA2BSLC6A2SLC6A4 | |
| SCHEMBL1320915 | 0.73 | KMT2A (0.40) | GABRA5GABRB2SLC6A1SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113302184-A | 1,3, 4-oxadiazolinone compounds and drugs | 日本新药株式会社 | 2021-08-24 | — | — | CN | disclosed |
| US-9630945-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-04-25 | — | — | US | disclosed |
| US-9409895-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2016-08-09 | — | — | US | disclosed |
| EP-2964654-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | Glaxosmithkline LLC (US) | 2016-01-13 | — | — | EP | disclosed |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2016-01-07 | — | — | US | disclosed |
| US-20150307475-A1 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-8901145-B2 | Aminopyrimidine kinase inhibitors | Jasco Pharmaceuticals, LLC (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2014138562-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-7759340-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-07-20 | — | — | US | disclosed |
| US-20090181955-A1 | Antibacterial Agents | MILLER WILLIAM HENRY | 2009-07-16 | — | — | US | disclosed |
| US-7511035-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2009-03-31 | — | — | US | disclosed |
| US-20080139539-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | GABRA5 258/4885GABRB2 606/4885SLC6A1 791/4885 |
| US-20150307475-A1 | Autotaxin inhibitors | ENPP2, ATXN10, ATXN2L | GABRA5 3785/4885GABRB2 3459/4885SLC6A1 2649/4885 |
| US-20080139539-A1 | Antibacterial Agents | NQO2, NQO1, NRDC | GABRA5 4213/4885GABRB2 4258/4885SLC6A1 4378/4885 |
| US-20090181955-A1 | Antibacterial Agents | NQO2, NQO1, NRDC | GABRA5 4213/4885GABRB2 4258/4885SLC6A1 4378/4885 |
| US-20160002273-A1 | THIENO[3,2-D]PYRIMIDINE-6-CARBOXAMIDES AND ANALOGUES AS SIRTUIN MODULATORS | SIRT2, SIRT1, SIRT6 | GABRA5 3237/4885GABRB2 2724/4885SLC6A1 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.